Funding round brings in $20M for Alzheimer's drug developer

05/24/2013 | MedCityNews.com

Acumen Pharmaceuticals has pulled in $20 million in a Series A funding round from BVF Partners, NeuroVentures Fund and other investors. Proceeds will go toward preclinical development of the firm's Alzheimer's disease drug candidate, an antibody that targets soluble oligomers of the amyloid beta peptide in the brain.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC